# FDA Approves Casgevy Label Expansion for Pediatric Sickle Cell Disease and Beta Thalassemia

> fda · REPORTED · 2026-07-02

The FDA approved an expanded label for Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) to include patients ages two and older with sickle cell disease or transfusion-dependent beta thalassemia. The CRISPR-based gene therapy is the first of its kind to receive this pediatric expansion.

About Vertex Pharmaceuticals: Vertex Pharmaceuticals is a global biopharmaceutical company that develops transformative medicines for serious diseases, including its CRISPR-based gene therapy Casgevy, developed with CRISPR Therapeutics, targeting blood disorders.

- Company: Vertex Pharmaceuticals
- Sector: biotech
- Primary source: https://tldrbio.tech/p/biotech-pharma-updates-july-2-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.